Novel 3D Imaging Offers New Tool for Identifying Advanced Fibrosis in Liver

UC San Diego School of Medicine NAFLD Research Center finds MRE imaging provides highly accurate, less invasive method —

Nonalcoholic fatty liver disease, or NAFLD, comprises a group of liver disorders whose prevalence is widespread and rising. It’s estimated that at least one-third of Americans have NAFLD; among obese persons, the figure is 50 percent. … Read the Full Story from the UC San Diego Newsroom


Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc, Director of the NAFLD Research Center, is first author of the study report in The American Journal of Gastroenterology.

Dr. Loomba is Professor of Medicine in the Division of Gastroenterology, Department of Medicine; and Adjunct Professor in the Division of Epidemiology, Department of Family and Preventive Medicine.

Dr. Bernd Schnabl and Coworkers Find Another Way Alcohol Damages the Liver

Natural gut antibiotics diminished by alcohol leave mice more prone to bacterial growth in the liver, exacerbating alcohol-induced liver disease —

Alcohol itself can directly damage liver cells. Now researchers at University of California, San Diego School of Medicine report evidence that alcohol is also harmful to the liver for a second reason — it allows gut bacteria to migrate to the liver, promoting alcohol-induced liver disease. The study, conducted in mice and in laboratory samples, is published February 10 in Cell Host & Microbe.

“Alcohol appears to impair the body’s ability to keep microbes in check,” said senior author Bernd Schnabl, MD, associate professor of gastroenterology at UC San Diego School of Medicine. … Read the Full Story from the UC San Diego Newsroom


BBernd Schnabl, MDernd Schnabl, MD, is Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine.

Division of Gastroenterology and Hepatology faculty members Samuel B. Ho, MD, Professor of Medicine; and David A. Brenner, MD, Vice Chancellor, Health Sciences, Dean of UC San Diego School of Medicine and Professor of Medicine are coauthors of the study report.

Read the Article Abstract

Dr. Schnabl’s Laboratory Website

UC San Diego Launches New Nonalcoholic Fatty Liver Disease Research Center

Roughly one-quarter of all Americans – an estimated 100 million adults and children – have nonalcoholic fatty liver disease (NAFLD), a chronic condition that can lead to cirrhosis, liver cancer and liver failure. Combining a diverse array of basic science, biomarkers, imaging and clinical efforts, University of California, San Diego School of Medicine has launched a new NAFLD Research Center to better understand the disease and develop treatments where none currently exist.

“We already have a lot of depth and breadth in the study and treatment of NAFLD and associated conditions at UC San Diego,” said Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology and director of the new center. … Read the full story from the UC San Diego Newsroom


Rohit Loomba, MDNAFLD Research Center director Rohit Loomba, MD, MHSc, is Professor of Clinical Medicine and Associate Director of Clinical Research in the Division of Gastroenterology and Hepatology.

He is a clinical and translational physician-scientist who focuses his work on chronic liver diseases with particular attention to nonalcoholic fatty liver disease (NAFLD). He is an internationally recognized expert in translational research and innovative clinical trial design in NAFLD and nonalcoholic steatohepatitis (NASH) and hepatic fibrosis.

He directs the NAFLD Clinic at UC San Diego Medical Center.

Dr. Loomba became a member of the Division of Gastroenterology faculty in 2009, when he graduated from the UC San Diego Gastroenterology Fellowship Program. He received his clinical and research training in advanced hepatology at the National Institutes of Health.

He holds an adjunct faculty appointment in the UC San Diego Division of Epidemiology, Department of Family Medicine and Public Health at UC San Diego.

Fatty Liver Disease and Scarring Have Strong Genetic Component

Researchers at the University of California, San Diego School of Medicine say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.

The findings are published online in the journal Gastroenterology. … Read the Full Story from the UC San Diego Newsroom

New Drug Combination Treats Hepatitis C Patients Also Infected with HIV

Novel treatment has 97 percent success rate in co-infected patients —

Roughly 20 to 30 percent of patients with hepatitis C virus (HCV) are also infected with human immunodeficiency virus type 1 (HIV). Both blood-borne viruses share the same modes of transmission, but many HCV medications currently have significant limitations due to adverse interactions with HIV treatments. Researchers at University of California, San Diego School of Medicine report a new combination that effectively treats HCV in patients co-infected with HIV. … Read the full story from the UC San Diego News Center


David L. Wyles, MD, is lead author of the New England Journal of Medicine article that reports the results of the multi-center study. Dr. Wyles is associate professor of clinical medicine in the Division of Infectious Diseases.

Read the article online:

Wyles D.L., Ruane P.J., Sulkowski M.S., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal of Medicine July 21, 2015, 10.1056/NEJMoa1503153.  Free full text

UC San Diego Health System Retains #1 Ranking

US News & World Report Cites Region’s Only Academic Health System Among Nation’s Best 

UC San Diego Health System remains among the nation’s best, according to the U.S. News & World Report’s 2014-15 issue of “America’s Best Hospitals,” released this week. The magazine’s widely cited findings again placed UC San Diego Health System first in the San Diego metropolitan area and fifth in California, with national rankings in 11 specialties, up from 10 last year. This is comparable to the country’s most prestigious health care institutions.  Read the full story from the UCSD Newsroom


Sulpizio Cardiovascular CenterUC San Diego Health System is nationally ranked in eleven medical specialties, including seven in the Department of Medicine:  Cancer, Cardiology, Endocrinology & Diabetes, Gastroenterology, Geriatrics, Nephrology, Pulmonology and Rheumatology.

UC San Diego-Human Longevity Inc. Agreement Seeks to Accelerate Medical Science

Thousands of patient genomes expected to fuel diverse medical research, beginning with cancer

The new collaborative research agreement between Human Longevity Inc. (HLI) and the University of California, San Diego, announced today, represents a significant and necessary step in efforts to research and translate the potential of the human genome into novel and real treatments and therapies able to change and improve the human condition.

“This agreement brings together the resources of two entities that, in combination, may ultimately help improve countless lives,” said David A. Brenner, MD, vice chancellor of health sciences at UC San Diego and dean of the UC San Diego School of Medicine. “HLI aims to bring leading-edge thinking in genomics technologies. UC San Diego boasts some of the world’s finest researchers and physicians working at places like the Moores Cancer Center. Together, we will collaborate to marshal the people, the tools and the resources to really make a difference in human health.” … Read the full story from the UC San Diego News Center

Dr. David Brenner Speaking at Grand Rounds March 13

David A. Brenner, MD Speaking at Medicine Grand Rounds on March 13 is Dr. David A. Brenner, vice chancellor for health sciences, dean of the UCSD School of Medicine and professor of medicine in the Division of Gastroenterology.

A physician-scientist, Brenner is widely respected for his translational research in liver disease. He will speak at Grand Rounds on new approaches to therapy for fibrosis.

Brenner is a member of numerous honorific societies including the American Society of Clinical Investigation, the American College of Physicians and the Association of American Physicians, of which he is immediate Past President. Last year, he was elected to the Institute of Medicine.

UC San Diego press releases about his recent research:

Read Dr. Brenner’s School of Medicine Biography

About Medicine Grand Rounds

UCSD’s Medicine Grand Rounds is held weekly on Wednesday mornings, 7:30 – 8:30 a.m., in the Liebow Auditorium, second floor, Biomedical Sciences Building on the UCSD School of Medicine Campus. There is a hiatus in summer.

To see this year’s schedule and find video viewing information, visit the Medicine Grand Rounds page on the Department of Medicine website.

Dr. Rohit Loomba on Fatty Liver Disease: HHMI Bulletin

Dr. Rohit LoombaDr. Rohit Loomba, a UCSD hepatologist who specializes in fatty liver disease, is interviewed in an article about the disease in the Fall 2012 health bulletin from the Howard Hughes Medical Institute.

In “The Fat You Can’t See,” Loomba describes the rising incidence of fatty liver disease and points to society’s general increase in dietary sugar intake as a major cause. He emphasizes the importance of identifying individuals who are at highest risk for developing the disease and he predicts there will be a dramatic increase in our understanding of the disease in the next five years.

Rohit Loomba, MD, MHSc, is assistant professor of clinical medicine in the Division of Gastroenterology. He also holds an appointment in the Division of Epidemiology in the Department of Family and Preventive Medicine.

Loomba conducts his clinical practice in UC San Diego Health System’s liver disease clinics. In his research laboratory, he conducts a variety of studies of nonalcoholic fatty liver disease (NAFLD), including a number of clinical trials.

With a four-year mentored patient-oriented research career development grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Loomba is investigating the genetic epidemiology of NAFLD in a twin-pair study. In that work, his mentors are UCSD researchers Daniel T. O’Connor, MD, professor of medicine and pharmacology; Elizabeth Barrett-Connor, MD, distinguished professor and chief of the Division of Epidemiology in the Department of Family and Preventive Medicine; and David Brenner, MD, Vice Chancellor for Health Sciences and Dean of the School of Medicine.

Loomba serves as the UCSD site principal investigator for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH-CRN) studies in adult patients with NAFLD. NASH-CRN, an NIDDK-sponsored research consortium funded via a UO1 research program-cooperative agreement mechanism, aims to improve understanding of the natural history, pathophysiology and management of NAFLD.

In addition, he is the founding director and principal investigator of the San Diego Integrated NAFLD Research Consortium (SINC), which includes four centers: UCSD, Kaiser Permanente Health System, Sharp Health System, and Balboa Naval Medical Center. SINC is a collaborative network that allows community-based patients to participate in NAFLD studies conducted at UCSD.

Loomba has established a major NAFLD research program at UCSD with recently published investigator-initiated treatment studies in NASH (Le et al., Hepatology September 2012) and several in progress.

In various NAFLD translational research studies currently ongoing at UCSD, Loomba collaborates with Drs. Jerrold Olefsky, David Brenner, Claude Sirlin, Bernd Schnabl, Lars Eckmann, Edward Dennis, Ariel Feldstein and Ekihiro Seki.

He also directs the UCSD fellowship training program in liver epidemiology and patient-oriented outcomes research.

More Information:

Two from UCSD School of Medicine Named Members of the Institute of Medicine

The Institute of Medicine (IOM) today announced the names of 70 new members and 10 foreign associates during its 42nd annual meeting.  Included are two new members from the University of California, San Diego School of Medicine: David A. Brenner, MD, vice chancellor for Health Sciences and dean of the UCSD School of Medicine, and Don W. Cleveland, PhD, chair of the UCSD Department of Cellular and Molecular Medicine, and professor of medicine, neurosciences, and cellular and molecular medicine at the Ludwig Institute for Cancer Research. … Read the full story from the UCSD Newsroom


Dr. David BrennerA translational researcher, Dr. David Brenner investigates the molecular pathogenesis of fibrotic liver disease and the genetic basis of  liver disorders. He is a member of the Division of Gastroenterology in the Department of Medicine.  |  Read his academic biography